The ADA abstract submission is a formal, structured summary of original research intended for review and potential presentation at medical conferences hosted by the American Diabetes Association. Submissions must include a clear objective, methods, results, and conclusion within strict word limits and formatting standards.
Abstracts submitted to the ADA are evaluated for scientific merit, novelty, and relevance to diabetes care, prevention, and research. They serve as the primary screening tool for session selection and are typically limited to 300-400 words. The process is managed through the ADA's online submission portal, which enforces formatting rules such as font size, line spacing, and section headings.
Failure to follow the official guidelines results in automatic rejection. For example, using bold text in the body or exceeding character limits leads to disqualification. The 2023 ADA Scientific Sessions required submissions to use 12-point Times New Roman, single-spaced lines, and a maximum of 300 words. All abstracts undergo peer review by a committee of experts in endocrinology and clinical research.
Submission begins with registration on the ADA's official conference portal. Authors must create an account, assign roles (e.g., presenting author, co-author), and upload the abstract in a specified format. The system validates file type, word count, and section structure before allowing final submission.
Each abstract must contain four mandatory sections: Background, Methods, Results, and Conclusion. These sections are not labeled with headers in the final printed program but are required during submission for reviewer clarity. The Background explains the research gap; Methods detail study design and population; Results present key findings with statistical values; Conclusion states implications.
For instance, a 2022 submission titled "Glycemic Control in Type 2 Diabetes Using Continuous Glucose Monitoring in Rural Populations" included: Background (15 words), Methods (60 words), Results (85 words), and Conclusion (40 words). Total word count was 285. This abstract was accepted and presented in the Clinical Trials session.
ADA abstracts must avoid jargon, passive voice, and vague language. Phrases like "showed promising results" are unacceptable. Instead, state specific outcomes: "HbA1c decreased by 1.2% (p = 0.003) over 12 weeks." The association cites the Diabetes Care journal's editorial standards as a reference for clarity and precision.
A common mistake is misidentifying the presenting author. Only one individual may be listed as the presenter, and they must be available to attend the conference. If the presenting author cannot attend, the abstract is withdrawn unless a replacement is approved in writing.
Another frequent error is including references. The ADA prohibits citations in abstracts. Any reference material must be omitted or replaced with parenthetical summaries. For example, instead of "(Smith et al., 2021)", write "previous studies show similar trends."
Submissions fall into three categories based on research type:
| Type | Scope | Word Limit | Example Topic |
|---|---|---|---|
| Original Research | Clinical trials, observational studies, randomized controlled trials | 300 words | Effect of GLP-1 agonists on weight loss in prediabetes |
| Case Reports | Unique patient presentations with diagnostic or therapeutic insights | 250 words | Atypical presentation of diabetic ketoacidosis in a young adult |
| Quality Improvement | Program evaluations, process changes, health systems interventions | 300 words | Implementation of telehealth in rural diabetes clinics |
Each category has distinct evaluation criteria. Original research is assessed on statistical rigor and reproducibility. Case reports are judged on clinical significance and educational value. Quality improvement submissions are reviewed for scalability and impact on patient outcomes.
Some researchers assume that submitting an abstract guarantees presentation. That is incorrect. Acceptance rates average 40-50% annually, depending on session availability and thematic alignment. A high-quality abstract may still be rejected due to oversubscription in a popular track.
Another misconception is that abstracts can be revised after submission. Once locked, edits are not permitted. Authors must submit final versions. The 2023 deadline was June 15 at 11:59 PM Eastern Time. Late entries were not processed.
I submitted my first ADA abstract in 2021. I spent three days refining the Results section to include exact p-values and confidence intervals. After initial rejection for exceeding the word limit, I removed two sentences from the Background and reduced the Methods section by 15 words. The revised version was accepted.
One non-obvious tip: use the "preview mode" in the submission portal. It simulates how the abstract will appear in the final program, revealing formatting issues like line breaks in the middle of words or missing spaces between sections.
Always proofread for typos. A single misplaced comma in the Methods section caused confusion in one 2022 submission, leading to a request for clarification. The author corrected it and was accepted.
The ADA abstract submission process demands precision, brevity, and adherence to strict guidelines. Success hinges on clear structure, accurate data presentation, and compliance with formatting rules. Submit early, use preview tools, and avoid common errors like citations and word count violations. Following these steps increases the likelihood of acceptance at a major diabetes research conference.